Ankylosing Spondylitis Market 2024 - By Size, Share, Growth, Regional Insights, Analysis Report And Forecast To 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Ankylosing Spondylitis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $7.89 billion In 2028 At A CAGR Of 7.7%.

The ankylosing spondylitis market size has grown strongly in recent years. It will grow from $5.41 billion in 2023 to $5.86 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to hla-b27 discovery, biologic treatments development, pain management approaches, patient advocacy and awareness, nsaids and disease modifying drugs.

The ankylosing spondylitis market size is expected to see strong growth in the next few years. It will grow to $7.89 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to personalized medicine approach, novel biologics development, early intervention and screening, lifestyle and diet management, telemedicine and remote monitoring. Major trends in the forecast period include biosimilar availability, targeted pain therapies, patient-reported outcomes (pros) emphasis, community support programs, regenerative medicine exploration.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Ankylosing Spondylitis Market Major Segments
The ankylosing spondylitis market covered in this report is segmented -

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery
2) By Molecule: Biologics, Biosimilar, Small Molecules
3) By Route of Administration: Parenteral, Oral, Other Routes
4) By Application: Juveniles, Adults
5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

Key Driver - Ankylosing Spondylitis Market Surges With The Growing Geriatric Population Worldwide

The increasing geriatric population is expected to propel the growth of the ankylosing spondylitis market going forward. The geriatric population refers to an increase in the proportion of elderly people due to changes in the age structure of a population. This demographic shift has increased the number and proportion of people over the age of 60. Ankylosing spondylitis treatment and drugs help to improve mobility and manage pain in the geriatric population having ankylosing spondylitis condition. For instance, in October 2022, according to World Health Organization, a Switzerland-based international public health organization, by 2030, 1 out of 6 people in the world will be aged more than 60 years or above, and in 2020, there was a rise in 1 billion aged people reaching to 1.4 billion. Therefore, the increasing geriatric population is driving the growth of the ankylosing spondylitis market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=11962&type=smp

Prominent Trend - Advancements In Therapeutic Options Drive Growth In The Ankylosing Spondylitis Market

The advancements in therapeutic options are a key trend gaining popularity in the ankylosing spondylitis market. Companies operating in ankylosing spondylitis are advancing new therapeutic options to sustain their position in the market. For instance, in December 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology company received FDA approval for XELJANZ (tofacitinib) for the treatment of active ankylosing spondylitis. XELJANZ (tofacitinib) is a Janus kinase (JAK) inhibitor effective for five immuno-inflammatory conditions. This medication is effective against intolerance or inadequate response to one or more tumor necrosis factor (TNF) blockers. The XELJANZ (tofacitinib) does not require infusion or injection to deliver the medication.

Ankylosing Spondylitis Market Players
Major companies operating in the ankylosing spondylitis market report are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Sandoz International GmbH, Reliance Life Sciences Pvt. Ltd., Affibody Medical AB

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the ankylosing spondylitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Ankylosing Spondylitis Market Report Structure
3. Ankylosing Spondylitis Market Trends And Strategies
4. Ankylosing Spondylitis Market - Macro Economic Scenario
5. Ankylosing Spondylitis Market Size And Growth
…..
27. Ankylosing Spondylitis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.